Global Engineered T Cells

Engineered T Cells Comprehensive Study by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor (TCR), Chimeric Antigen Receptor (CAR)), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, Others), End User (Hospitals, Cancer Research Centers, Clinics) Players and Region - Global Market Outlook to 2030

Engineered T Cells Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Engineered T Cells
Increasing in the incidence of lung cancer and high utilization of engineered T cells for the treatment of lung cancer will help to fuel global engineered T cell market in the forecasted period. Engineered T cells are also called as specifically modified T cells. Engineered T cells are specially designed for the treatment of primary immune deficiencies, autoimmune diseases, and cancer. It enables the decrease of toxicities as well as prevent antigen escape. It is also used in skin diseases, cardiovascular, orthopedic problems, and neurodegenerative diseases, immune deficient disorders.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia- Pacific
UnitValue (USD Million)


Engineered T Cells is a fragmented market due to the presence of various players. The players are focusing on strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Engineered T Cells market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Autolus Limited (United Kingdom), Bellicum Pharmaceuticals, Inc. (United States), Cells Medica (United Kingdom), Elli Lilly and Company (United States), Gilead Sciences, Inc. (United States), Juno Therapeutics (United States), Novartis AG (Switzerland), Oxford Biomedica (United Kingdom), Pfizer Inc. (United States) and Precision Bioscience. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Redmile Group LLC (United States), Seeking Alpha (United States) and Unum Therapeutics Inc (United States).

Segmentation Overview
AMA Research has segmented the market of Global Engineered T Cells market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor (TCR) and Chimeric Antigen Receptor (CAR)), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia and Others) and Region.



On the basis of geography, the market of Engineered T Cells has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Engineered T Cells market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Government Support towards Modernized Healthcare Infrastructure, Technological Advancement In Established Nations and High Adoption Due to various Advantages such as Targeted Drug delivery and Fewer Side Effects

Market Growth Drivers:
High Demand due to Growing Prevalences of Various Types of Cancers and Growing Demand For Biopharmaceutical Therapies

Challenges:
Stringent Government Regulation Regarding FDA Approval

Restraints:
Rising Concern about High Cost oF Treatment and Risk Associated with Engineered T Cell Treatments

Opportunities:
Huge Demand in Emerging Countries and The Upsurge in Technological Advancement and R&D in Engineered T Cells

Market Leaders and their expansionary development strategies
In April 2019, Kite, a Gilead Company has announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. It offers a variety of chimeric antigen receptor T (CAR T) therapies, such as Yescarta (axicabtagene ciloleucel), Kite’s first commercially available CAR T cancer therapy, and investigational T cell receptor (TCR) cell therapies being assessed in solid tumors.
In April 2023, Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it has selected Cardinal Health Inc, to support the launch and commercialization of its CAR T-cell therapies in the United States, subject to FDA approval.


Key Target Audience
Treatment Providers, Healthcare Industries, Medical Institutes, Government Regulatory Bodies, Government And private Research Organization and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Tumor Infiltrating Lymphocytes
  • T Cell Receptor (TCR)
  • Chimeric Antigen Receptor (CAR)
By Application
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Leukemia
  • Others
By End User
  • Hospitals
  • Cancer Research Centers
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Demand due to Growing Prevalences of Various Types of Cancers
      • 3.2.2. Growing Demand For Biopharmaceutical Therapies
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulation Regarding FDA Approval
    • 3.4. Market Trends
      • 3.4.1. Government Support towards Modernized Healthcare Infrastructure
      • 3.4.2. Technological Advancement In Established Nations
      • 3.4.3. High Adoption Due to various Advantages such as Targeted Drug delivery and Fewer Side Effects
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Engineered T Cells, by Type, Application, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Engineered T Cells (Value)
      • 5.2.1. Global Engineered T Cells by: Type (Value)
        • 5.2.1.1. Tumor Infiltrating Lymphocytes
        • 5.2.1.2. T Cell Receptor (TCR)
        • 5.2.1.3. Chimeric Antigen Receptor (CAR)
      • 5.2.2. Global Engineered T Cells by: Application (Value)
        • 5.2.2.1. Lung Cancer
        • 5.2.2.2. Breast Cancer
        • 5.2.2.3. Colorectal Cancer
        • 5.2.2.4. Melanoma
        • 5.2.2.5. Leukemia
        • 5.2.2.6. Others
      • 5.2.3. Global Engineered T Cells by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Cancer Research Centers
        • 5.2.3.3. Clinics
      • 5.2.4. Global Engineered T Cells Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Engineered T Cells: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Autolus Limited (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bellicum Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cells Medica (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Elli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Gilead Sciences, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Juno Therapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Oxford Biomedica (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Precision Bioscience. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Engineered T Cells Sale, by Type, Application, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Engineered T Cells (Value)
      • 7.2.1. Global Engineered T Cells by: Type (Value)
        • 7.2.1.1. Tumor Infiltrating Lymphocytes
        • 7.2.1.2. T Cell Receptor (TCR)
        • 7.2.1.3. Chimeric Antigen Receptor (CAR)
      • 7.2.2. Global Engineered T Cells by: Application (Value)
        • 7.2.2.1. Lung Cancer
        • 7.2.2.2. Breast Cancer
        • 7.2.2.3. Colorectal Cancer
        • 7.2.2.4. Melanoma
        • 7.2.2.5. Leukemia
        • 7.2.2.6. Others
      • 7.2.3. Global Engineered T Cells by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Cancer Research Centers
        • 7.2.3.3. Clinics
      • 7.2.4. Global Engineered T Cells Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Engineered T Cells: by Type(USD Million)
  • Table 2. Engineered T Cells Tumor Infiltrating Lymphocytes , by Region USD Million (2018-2023)
  • Table 3. Engineered T Cells T Cell Receptor (TCR) , by Region USD Million (2018-2023)
  • Table 4. Engineered T Cells Chimeric Antigen Receptor (CAR) , by Region USD Million (2018-2023)
  • Table 5. Engineered T Cells: by Application(USD Million)
  • Table 6. Engineered T Cells Lung Cancer , by Region USD Million (2018-2023)
  • Table 7. Engineered T Cells Breast Cancer , by Region USD Million (2018-2023)
  • Table 8. Engineered T Cells Colorectal Cancer , by Region USD Million (2018-2023)
  • Table 9. Engineered T Cells Melanoma , by Region USD Million (2018-2023)
  • Table 10. Engineered T Cells Leukemia , by Region USD Million (2018-2023)
  • Table 11. Engineered T Cells Others , by Region USD Million (2018-2023)
  • Table 12. Engineered T Cells: by End User(USD Million)
  • Table 13. Engineered T Cells Hospitals , by Region USD Million (2018-2023)
  • Table 14. Engineered T Cells Cancer Research Centers , by Region USD Million (2018-2023)
  • Table 15. Engineered T Cells Clinics , by Region USD Million (2018-2023)
  • Table 16. South America Engineered T Cells, by Country USD Million (2018-2023)
  • Table 17. South America Engineered T Cells, by Type USD Million (2018-2023)
  • Table 18. South America Engineered T Cells, by Application USD Million (2018-2023)
  • Table 19. South America Engineered T Cells, by End User USD Million (2018-2023)
  • Table 20. Brazil Engineered T Cells, by Type USD Million (2018-2023)
  • Table 21. Brazil Engineered T Cells, by Application USD Million (2018-2023)
  • Table 22. Brazil Engineered T Cells, by End User USD Million (2018-2023)
  • Table 23. Argentina Engineered T Cells, by Type USD Million (2018-2023)
  • Table 24. Argentina Engineered T Cells, by Application USD Million (2018-2023)
  • Table 25. Argentina Engineered T Cells, by End User USD Million (2018-2023)
  • Table 26. Rest of South America Engineered T Cells, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Engineered T Cells, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Engineered T Cells, by End User USD Million (2018-2023)
  • Table 29. Asia Pacific Engineered T Cells, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Engineered T Cells, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Engineered T Cells, by Application USD Million (2018-2023)
  • Table 32. Asia Pacific Engineered T Cells, by End User USD Million (2018-2023)
  • Table 33. China Engineered T Cells, by Type USD Million (2018-2023)
  • Table 34. China Engineered T Cells, by Application USD Million (2018-2023)
  • Table 35. China Engineered T Cells, by End User USD Million (2018-2023)
  • Table 36. Japan Engineered T Cells, by Type USD Million (2018-2023)
  • Table 37. Japan Engineered T Cells, by Application USD Million (2018-2023)
  • Table 38. Japan Engineered T Cells, by End User USD Million (2018-2023)
  • Table 39. India Engineered T Cells, by Type USD Million (2018-2023)
  • Table 40. India Engineered T Cells, by Application USD Million (2018-2023)
  • Table 41. India Engineered T Cells, by End User USD Million (2018-2023)
  • Table 42. South Korea Engineered T Cells, by Type USD Million (2018-2023)
  • Table 43. South Korea Engineered T Cells, by Application USD Million (2018-2023)
  • Table 44. South Korea Engineered T Cells, by End User USD Million (2018-2023)
  • Table 45. Taiwan Engineered T Cells, by Type USD Million (2018-2023)
  • Table 46. Taiwan Engineered T Cells, by Application USD Million (2018-2023)
  • Table 47. Taiwan Engineered T Cells, by End User USD Million (2018-2023)
  • Table 48. Australia Engineered T Cells, by Type USD Million (2018-2023)
  • Table 49. Australia Engineered T Cells, by Application USD Million (2018-2023)
  • Table 50. Australia Engineered T Cells, by End User USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Engineered T Cells, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Engineered T Cells, by Application USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Engineered T Cells, by End User USD Million (2018-2023)
  • Table 54. Europe Engineered T Cells, by Country USD Million (2018-2023)
  • Table 55. Europe Engineered T Cells, by Type USD Million (2018-2023)
  • Table 56. Europe Engineered T Cells, by Application USD Million (2018-2023)
  • Table 57. Europe Engineered T Cells, by End User USD Million (2018-2023)
  • Table 58. Germany Engineered T Cells, by Type USD Million (2018-2023)
  • Table 59. Germany Engineered T Cells, by Application USD Million (2018-2023)
  • Table 60. Germany Engineered T Cells, by End User USD Million (2018-2023)
  • Table 61. France Engineered T Cells, by Type USD Million (2018-2023)
  • Table 62. France Engineered T Cells, by Application USD Million (2018-2023)
  • Table 63. France Engineered T Cells, by End User USD Million (2018-2023)
  • Table 64. Italy Engineered T Cells, by Type USD Million (2018-2023)
  • Table 65. Italy Engineered T Cells, by Application USD Million (2018-2023)
  • Table 66. Italy Engineered T Cells, by End User USD Million (2018-2023)
  • Table 67. United Kingdom Engineered T Cells, by Type USD Million (2018-2023)
  • Table 68. United Kingdom Engineered T Cells, by Application USD Million (2018-2023)
  • Table 69. United Kingdom Engineered T Cells, by End User USD Million (2018-2023)
  • Table 70. Netherlands Engineered T Cells, by Type USD Million (2018-2023)
  • Table 71. Netherlands Engineered T Cells, by Application USD Million (2018-2023)
  • Table 72. Netherlands Engineered T Cells, by End User USD Million (2018-2023)
  • Table 73. Rest of Europe Engineered T Cells, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe Engineered T Cells, by Application USD Million (2018-2023)
  • Table 75. Rest of Europe Engineered T Cells, by End User USD Million (2018-2023)
  • Table 76. MEA Engineered T Cells, by Country USD Million (2018-2023)
  • Table 77. MEA Engineered T Cells, by Type USD Million (2018-2023)
  • Table 78. MEA Engineered T Cells, by Application USD Million (2018-2023)
  • Table 79. MEA Engineered T Cells, by End User USD Million (2018-2023)
  • Table 80. Middle East Engineered T Cells, by Type USD Million (2018-2023)
  • Table 81. Middle East Engineered T Cells, by Application USD Million (2018-2023)
  • Table 82. Middle East Engineered T Cells, by End User USD Million (2018-2023)
  • Table 83. Africa Engineered T Cells, by Type USD Million (2018-2023)
  • Table 84. Africa Engineered T Cells, by Application USD Million (2018-2023)
  • Table 85. Africa Engineered T Cells, by End User USD Million (2018-2023)
  • Table 86. North America Engineered T Cells, by Country USD Million (2018-2023)
  • Table 87. North America Engineered T Cells, by Type USD Million (2018-2023)
  • Table 88. North America Engineered T Cells, by Application USD Million (2018-2023)
  • Table 89. North America Engineered T Cells, by End User USD Million (2018-2023)
  • Table 90. United States Engineered T Cells, by Type USD Million (2018-2023)
  • Table 91. United States Engineered T Cells, by Application USD Million (2018-2023)
  • Table 92. United States Engineered T Cells, by End User USD Million (2018-2023)
  • Table 93. Canada Engineered T Cells, by Type USD Million (2018-2023)
  • Table 94. Canada Engineered T Cells, by Application USD Million (2018-2023)
  • Table 95. Canada Engineered T Cells, by End User USD Million (2018-2023)
  • Table 96. Mexico Engineered T Cells, by Type USD Million (2018-2023)
  • Table 97. Mexico Engineered T Cells, by Application USD Million (2018-2023)
  • Table 98. Mexico Engineered T Cells, by End User USD Million (2018-2023)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Engineered T Cells: by Type(USD Million)
  • Table 110. Engineered T Cells Tumor Infiltrating Lymphocytes , by Region USD Million (2025-2030)
  • Table 111. Engineered T Cells T Cell Receptor (TCR) , by Region USD Million (2025-2030)
  • Table 112. Engineered T Cells Chimeric Antigen Receptor (CAR) , by Region USD Million (2025-2030)
  • Table 113. Engineered T Cells: by Application(USD Million)
  • Table 114. Engineered T Cells Lung Cancer , by Region USD Million (2025-2030)
  • Table 115. Engineered T Cells Breast Cancer , by Region USD Million (2025-2030)
  • Table 116. Engineered T Cells Colorectal Cancer , by Region USD Million (2025-2030)
  • Table 117. Engineered T Cells Melanoma , by Region USD Million (2025-2030)
  • Table 118. Engineered T Cells Leukemia , by Region USD Million (2025-2030)
  • Table 119. Engineered T Cells Others , by Region USD Million (2025-2030)
  • Table 120. Engineered T Cells: by End User(USD Million)
  • Table 121. Engineered T Cells Hospitals , by Region USD Million (2025-2030)
  • Table 122. Engineered T Cells Cancer Research Centers , by Region USD Million (2025-2030)
  • Table 123. Engineered T Cells Clinics , by Region USD Million (2025-2030)
  • Table 124. South America Engineered T Cells, by Country USD Million (2025-2030)
  • Table 125. South America Engineered T Cells, by Type USD Million (2025-2030)
  • Table 126. South America Engineered T Cells, by Application USD Million (2025-2030)
  • Table 127. South America Engineered T Cells, by End User USD Million (2025-2030)
  • Table 128. Brazil Engineered T Cells, by Type USD Million (2025-2030)
  • Table 129. Brazil Engineered T Cells, by Application USD Million (2025-2030)
  • Table 130. Brazil Engineered T Cells, by End User USD Million (2025-2030)
  • Table 131. Argentina Engineered T Cells, by Type USD Million (2025-2030)
  • Table 132. Argentina Engineered T Cells, by Application USD Million (2025-2030)
  • Table 133. Argentina Engineered T Cells, by End User USD Million (2025-2030)
  • Table 134. Rest of South America Engineered T Cells, by Type USD Million (2025-2030)
  • Table 135. Rest of South America Engineered T Cells, by Application USD Million (2025-2030)
  • Table 136. Rest of South America Engineered T Cells, by End User USD Million (2025-2030)
  • Table 137. Asia Pacific Engineered T Cells, by Country USD Million (2025-2030)
  • Table 138. Asia Pacific Engineered T Cells, by Type USD Million (2025-2030)
  • Table 139. Asia Pacific Engineered T Cells, by Application USD Million (2025-2030)
  • Table 140. Asia Pacific Engineered T Cells, by End User USD Million (2025-2030)
  • Table 141. China Engineered T Cells, by Type USD Million (2025-2030)
  • Table 142. China Engineered T Cells, by Application USD Million (2025-2030)
  • Table 143. China Engineered T Cells, by End User USD Million (2025-2030)
  • Table 144. Japan Engineered T Cells, by Type USD Million (2025-2030)
  • Table 145. Japan Engineered T Cells, by Application USD Million (2025-2030)
  • Table 146. Japan Engineered T Cells, by End User USD Million (2025-2030)
  • Table 147. India Engineered T Cells, by Type USD Million (2025-2030)
  • Table 148. India Engineered T Cells, by Application USD Million (2025-2030)
  • Table 149. India Engineered T Cells, by End User USD Million (2025-2030)
  • Table 150. South Korea Engineered T Cells, by Type USD Million (2025-2030)
  • Table 151. South Korea Engineered T Cells, by Application USD Million (2025-2030)
  • Table 152. South Korea Engineered T Cells, by End User USD Million (2025-2030)
  • Table 153. Taiwan Engineered T Cells, by Type USD Million (2025-2030)
  • Table 154. Taiwan Engineered T Cells, by Application USD Million (2025-2030)
  • Table 155. Taiwan Engineered T Cells, by End User USD Million (2025-2030)
  • Table 156. Australia Engineered T Cells, by Type USD Million (2025-2030)
  • Table 157. Australia Engineered T Cells, by Application USD Million (2025-2030)
  • Table 158. Australia Engineered T Cells, by End User USD Million (2025-2030)
  • Table 159. Rest of Asia-Pacific Engineered T Cells, by Type USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Engineered T Cells, by Application USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Engineered T Cells, by End User USD Million (2025-2030)
  • Table 162. Europe Engineered T Cells, by Country USD Million (2025-2030)
  • Table 163. Europe Engineered T Cells, by Type USD Million (2025-2030)
  • Table 164. Europe Engineered T Cells, by Application USD Million (2025-2030)
  • Table 165. Europe Engineered T Cells, by End User USD Million (2025-2030)
  • Table 166. Germany Engineered T Cells, by Type USD Million (2025-2030)
  • Table 167. Germany Engineered T Cells, by Application USD Million (2025-2030)
  • Table 168. Germany Engineered T Cells, by End User USD Million (2025-2030)
  • Table 169. France Engineered T Cells, by Type USD Million (2025-2030)
  • Table 170. France Engineered T Cells, by Application USD Million (2025-2030)
  • Table 171. France Engineered T Cells, by End User USD Million (2025-2030)
  • Table 172. Italy Engineered T Cells, by Type USD Million (2025-2030)
  • Table 173. Italy Engineered T Cells, by Application USD Million (2025-2030)
  • Table 174. Italy Engineered T Cells, by End User USD Million (2025-2030)
  • Table 175. United Kingdom Engineered T Cells, by Type USD Million (2025-2030)
  • Table 176. United Kingdom Engineered T Cells, by Application USD Million (2025-2030)
  • Table 177. United Kingdom Engineered T Cells, by End User USD Million (2025-2030)
  • Table 178. Netherlands Engineered T Cells, by Type USD Million (2025-2030)
  • Table 179. Netherlands Engineered T Cells, by Application USD Million (2025-2030)
  • Table 180. Netherlands Engineered T Cells, by End User USD Million (2025-2030)
  • Table 181. Rest of Europe Engineered T Cells, by Type USD Million (2025-2030)
  • Table 182. Rest of Europe Engineered T Cells, by Application USD Million (2025-2030)
  • Table 183. Rest of Europe Engineered T Cells, by End User USD Million (2025-2030)
  • Table 184. MEA Engineered T Cells, by Country USD Million (2025-2030)
  • Table 185. MEA Engineered T Cells, by Type USD Million (2025-2030)
  • Table 186. MEA Engineered T Cells, by Application USD Million (2025-2030)
  • Table 187. MEA Engineered T Cells, by End User USD Million (2025-2030)
  • Table 188. Middle East Engineered T Cells, by Type USD Million (2025-2030)
  • Table 189. Middle East Engineered T Cells, by Application USD Million (2025-2030)
  • Table 190. Middle East Engineered T Cells, by End User USD Million (2025-2030)
  • Table 191. Africa Engineered T Cells, by Type USD Million (2025-2030)
  • Table 192. Africa Engineered T Cells, by Application USD Million (2025-2030)
  • Table 193. Africa Engineered T Cells, by End User USD Million (2025-2030)
  • Table 194. North America Engineered T Cells, by Country USD Million (2025-2030)
  • Table 195. North America Engineered T Cells, by Type USD Million (2025-2030)
  • Table 196. North America Engineered T Cells, by Application USD Million (2025-2030)
  • Table 197. North America Engineered T Cells, by End User USD Million (2025-2030)
  • Table 198. United States Engineered T Cells, by Type USD Million (2025-2030)
  • Table 199. United States Engineered T Cells, by Application USD Million (2025-2030)
  • Table 200. United States Engineered T Cells, by End User USD Million (2025-2030)
  • Table 201. Canada Engineered T Cells, by Type USD Million (2025-2030)
  • Table 202. Canada Engineered T Cells, by Application USD Million (2025-2030)
  • Table 203. Canada Engineered T Cells, by End User USD Million (2025-2030)
  • Table 204. Mexico Engineered T Cells, by Type USD Million (2025-2030)
  • Table 205. Mexico Engineered T Cells, by Application USD Million (2025-2030)
  • Table 206. Mexico Engineered T Cells, by End User USD Million (2025-2030)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Engineered T Cells: by Type USD Million (2018-2023)
  • Figure 5. Global Engineered T Cells: by Application USD Million (2018-2023)
  • Figure 6. Global Engineered T Cells: by End User USD Million (2018-2023)
  • Figure 7. South America Engineered T Cells Share (%), by Country
  • Figure 8. Asia Pacific Engineered T Cells Share (%), by Country
  • Figure 9. Europe Engineered T Cells Share (%), by Country
  • Figure 10. MEA Engineered T Cells Share (%), by Country
  • Figure 11. North America Engineered T Cells Share (%), by Country
  • Figure 12. Global Engineered T Cells share by Players 2023 (%)
  • Figure 13. Global Engineered T Cells share by Players (Top 3) 2023(%)
  • Figure 14. Global Engineered T Cells share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Autolus Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. Autolus Limited (United Kingdom) Revenue: by Geography 2023
  • Figure 18. Bellicum Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bellicum Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Cells Medica (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Cells Medica (United Kingdom) Revenue: by Geography 2023
  • Figure 22. Elli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Elli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 24. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Gilead Sciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Juno Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 27. Juno Therapeutics (United States) Revenue: by Geography 2023
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 30. Oxford Biomedica (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Oxford Biomedica (United Kingdom) Revenue: by Geography 2023
  • Figure 32. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Precision Bioscience. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Precision Bioscience. (United States) Revenue: by Geography 2023
  • Figure 36. Global Engineered T Cells: by Type USD Million (2025-2030)
  • Figure 37. Global Engineered T Cells: by Application USD Million (2025-2030)
  • Figure 38. Global Engineered T Cells: by End User USD Million (2025-2030)
  • Figure 39. South America Engineered T Cells Share (%), by Country
  • Figure 40. Asia Pacific Engineered T Cells Share (%), by Country
  • Figure 41. Europe Engineered T Cells Share (%), by Country
  • Figure 42. MEA Engineered T Cells Share (%), by Country
  • Figure 43. North America Engineered T Cells Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Autolus Limited (United Kingdom)
  • Bellicum Pharmaceuticals, Inc. (United States)
  • Cells Medica (United Kingdom)
  • Elli Lilly and Company (United States)
  • Gilead Sciences, Inc. (United States)
  • Juno Therapeutics (United States)
  • Novartis AG (Switzerland)
  • Oxford Biomedica (United Kingdom)
  • Pfizer Inc. (United States)
  • Precision Bioscience. (United States)
Additional players considered in the study are as follows:
Redmile Group LLC (United States) , Seeking Alpha (United States) , Unum Therapeutics Inc (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 240 Pages 75 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Engineered T Cells Quantitative research analysis
Global Engineered T Cells Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Autolus Limited (United Kingdom), Bellicum Pharmaceuticals, Inc. (United States), Cells Medica (United Kingdom), Elli Lilly and Company (United States), Gilead Sciences, Inc. (United States), Juno Therapeutics (United States), Novartis AG (Switzerland), Oxford Biomedica (United Kingdom), Pfizer Inc. (United States) and Precision Bioscience. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Government Support towards Modernized Healthcare Infrastructure " is seen as one of major influencing trends for Engineered T Cells Market during projected period 2023-2030.
The Engineered T Cells market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Engineered T Cells Report?

Have a Query? Click Here

Other Related Reports

Chronic Obstructive Pulmonary Disorder Comprehensive Study by Type (Chronic Bronchitis, Emphysema), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Medication Type (Bronchodi...
$ 3750
Camellia Oil Comprehensive Study by Type (Extra Virgin camellia Oil, Pure camellia Oil, Pomace camellia Oil), Application (Food, Cosmetics, Pharmaceuticals, Chemical Industry), Distribution Channel (...
$ 3500
HIV Diagnosis Comprehensive Study by Type (Consumables (Assays and Kits & Reagents, and other Consumables), Instruments, Software & Services), Test Type (Antibody Tests (HIV-1 Screening Tests, HIV-1 ...
$ 3750
Vitiligo Drug Comprehensive Study by Type (ARN-4079, ATI-50001, AX-1602, Ruxolitinib Phosphate, VLRX-001, Others), Application (Clinic, Hospital, Others), Route of Administration (Oral, Topical), Dis...
$ 3750
Nicotine Addiction Treatment Comprehensive Study by Type (OMS-527, AT-1001, CTDP-002, EORA-101, URB-694, Others), Application (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacies, Me...
$ 3750
Preventable Vaccines Comprehensive Study by Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Others), Application (Pneumococcal, Poliovirus, Hepatitis, Influen...
$ 3650